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Chronic wasting disease (CWD) and scrapie can be transmitted through indirect environmental routes,
possibly via soil, and a practical decontamination strategy for prion-contaminated soil is currently unavailable.
In the laboratory, an enzymatic treatment under environmentally relevant conditions (22°C, pH 7.4) can
degrade soil-bound PrPSc below the limits of Western blot detection. We developed and used a quantitative
serial protein misfolding cyclic amplification (PMCA) protocol to characterize the amplification efficiency of
treated soil samples relative to controls of known infectious titer. Our results suggest large (104- to >106-fold)
decreases in soil-bound prion infectivity following enzyme treatment, demonstrating that a mild enzymatic
treatment could effectively reduce the risk of prion disease transmission via soil or other environmental
surfaces.

Prion diseases, or transmissible spongiform encephalopathies (TSEs), are fatal neurodegenerative diseases that include
bovine spongiform encephalopathy (BSE) (“mad cow” disease),
scrapie in sheep and goats, chronic wasting disease (CWD) of
deer, elk, and moose, and Creutzfeldt-Jakob disease (CJD) in
humans (9, 10). The infectious agent of prion diseases is PrPSc,
an abnormally folded isoform of a normal cellular protein,
PrPc (5, 9, 19). Infectious CWD and scrapie prions are shed
from living hosts and present in carcasses and can remain
infectious after years in the environment (10, 18). The environment can serve as a long-term reservoir of prion infectivity,
which likely facilitates a sustained incidence of CWD in freeranging cervid populations and complicates efforts to eliminate
CWD and scrapie in captive herds (10). PrPSc has recently
been detected on gates and fencing at a farm where scrapie is
endemic (8), indicating that environmental surfaces can become contaminated with prions. Since prions are known to
sorb (i.e., bind) to a wide range of soils and soil minerals and
remain infectious (10–12, 15), soil may play an important role
in environmental transmission of prion diseases (10).
It is desirable to develop a practical, in situ method for
decontaminating soil and other environmental surfaces exposed to prions, since current best practices for prion decontamination, such as incineration, autoclaving, or harsh
chemical treatments, are not practical for most environmental applications. We have previously characterized an enzymebased treatment that is effective at degrading soil-bound CWD
PrPSc beyond the limits of Western blot detection at pH 7.4
and 22°C (14). Such a treatment has the potential to lower
or eliminate infectivity at identified or presumed CWD- and
scrapie-contaminated surfaces in captive and wild settings.

However, a number of studies have documented high levels of
prion infectivity in the absence of detectable PrPSc (2, 16).
Thus, the potential effectiveness of such an enzyme treatment
at decreasing the risk of prion transmission remains unclear.
The protein misfolding cyclic amplification (PMCA) method
(3, 17) has been used previously to detect low levels of prion
infectivity. For serial PMCA (sPMCA), brain homogenate,
soil, or other material containing an infectious prion seed is
added to uninfected brain tissue (containing PrPc) homogenized in a conversion buffer. The sample is then subjected to
repeated cycles of sonication followed by incubation at 37°C.
After a specified number of cycles (designated one PMCA
round), the samples are diluted in fresh uninfected brain
homogenate and subjected to additional cycles of sonication
and incubation. In this manner, very small amounts of PrPSc
are amplified through conversion of PrPc to PrPSc that can
be detected by standard Western blotting (3, 17). Moreover,
PMCA can also be used to compare prion replication efficiencies
(i.e., the ability to convert PrPc to PrPSc) (1, 15), and a strong
correlation between infectious prion titer and PMCA replication efficiency has been observed after one PMCA round (15).
Here we developed a serial (multiround) PMCA protocol for
correlating PMCA efficiency and infectious prion titer. The
objective of this study was to determine any changes in the
replication efficiency of soil-bound prions following enzymatic
treatment. Prions were adsorbed to a range of soil minerals
and whole soils, exposed to a bacterially derived subtilisin
enzyme solution, and then subjected to serial PMCA to compare the replication efficiencies of treated and untreated soilbound prions.
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Prion sources and tissue preparation. Tissue was collected from uninfected
hamsters or hamsters infected with the hyper (HY) strain of transmissible mink
encephalopathy (TME) agent, as previously described (13). Prion-infected brain
tissue was homogenized to 10% (wt/vol) in Dulbecco’s phosphate-buffered saline
(DPBS) without Ca2⫹ or Mg2⫹ (Mediatech, Herndon, VA) using strain-dedi-
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TABLE 1. Parameters used to generate soil-bound prions
Soil or
minerala
Rinda SCL soil
Bentonite clay
SiO2 powder
SiO2-HA
Fine quartz
sand

Adsorption
incubation
time (h)

Soil
concnb
(mg/ml)

Brain
homogenate
(%)

Amt imaged
for Fig. 1
(mg)

PMCA
spike
(1:100)
(mg)

24
24
24
168
168

5
5
50
10
50

0.5
0.5
0.25
0.5
0.5

0.5
0.5
5
1
10

0.1
0.1
2
1
10

a

SCL, silty clay loam; SiO2, silicon dioxide; HA, humic acid.
The total adsorption solution volume was 1 ml (SCL soil, bentonite clay,
SiO2, and SiO2-HA) or 200 l (sand).
b

cated Tenbroeck tissue grinders (Kontes, Vineland, NJ). For the PMCA substrate, uninfected hamster brain tissue was homogenized to 10% (wt/vol) in
ice-cold conversion buffer (DPBS [pH 7.4] containing 5 mM EDTA, 1% [vol/vol]
Triton X-100, and a complete protease inhibitor tablet [Roche Diagnostics,
Mannheim, Germany]) and centrifuged at 500 ⫻ g for 30 s. The supernatant was
collected and stored at ⫺80°C.
Prion soil adsorption. Prion soil adsorption was performed as described previously (14). Brain homogenate from hamsters infected with the HY TME agent
was combined with gamma-irradiated fine white sand, Rinda silty clay loam soil
(SCL soil), sodium bentonite clay, silicon dioxide powder (SiO2), or humic
acid-coated silica gel particles (SiO2-HA), all of which have been previously
characterized (12, 14). The sandy loam soil used previously (14) was not used in
this study as it is not compatible with the PMCA method (15). Soil-homogenate
mixtures (in 1⫻ DPBS) were gently rotated at 24 rpm at 22°C. The incubation
time and soil, buffer, and brain homogenate amounts were selected based on
previous studies (11, 12, 14, 15) and are detailed in Table 1. PrP adsorptions to
silty clay loam, bentonite clay, SiO2 powder, and SiO2-humic acid were conducted in a total volume of 1 ml in 1.5-ml polypropylene tubes (Fisher Scientific).
Due to its large particle size, quartz sand could not be processed in bulk and
aliquoted into smaller samples; thus, individual sand samples (10 mg) were
incubated with brain homogenate in a total volume of 0.2 ml in polypropylene
PCR tubes (Fisher Scientific). Samples were removed after incubation and centrifuged at 100 ⫻ g for 5 min. The supernatant was removed, and the pellets were
washed 5 times with DPBS.
Subtilisin enzyme treatment. For enzymatic treatment, soil pellets (amounts
are shown in Table 1) were exposed to an aqueous enzyme solution known as
Prionzyme M (Genencor/Danisco, Rochester, NY). The “Prionzyme” is a proprietary serine protease derived from a Bacillus subtilis strain (6), referred to
here as the “subtilisin.” Soil pellets were combined with a 10% Prionzyme dose
(the stock solution consisted of 100 Prionzyme units/gram in an aqueous solution
containing propylene glycol and sodium formate), and incubated undisturbed for
7 days at pH 7.4 and 22°C as described previously (14). All experiments were
performed in triplicate.
sPMCA. Serial protein misfolding cyclic amplification (sPMCA) was performed as described previously (15). Briefly, an initial prion seed was combined
with PMCA substrate (10% [wt/vol] uninfected brain homogenate in conversion
buffer [see above]) for a final volume of 100 l in 0.2-ml PCR tubes (Fisher
Scientific). The amount of soil used as an initial seed is shown in Table 1 for each
soil type. These amounts correspond approximately to a 1:100 initial dilution
(infectious seed/uninfectious substrate) (15). Samples were then subjected to
alternating cycles of sonication and incubation at 37°C. Sonication was performed with a Misonix 4000 sonicator (Misonix, Farmingdale, NY) with amplitude set to level 75, generating an average output of 160 W during each sonication cycle. After 24 h (one PMCA round), an aliquot of the samples was added
to fresh PMCA substrate and subjected to a second round of PMCA. Two
protocols were used for sonication length and interround dilution. Protocol 1
used 25 s of sonication followed by 9 min 35 s of incubation at 37°C, and samples
were diluted 1:1 between rounds. Protocol 2 used 5 s of sonication followed by
10 min of incubation at 37°C, and samples were diluted 1:20 between rounds.
Following PMCA, all samples were analyzed by Western blotting for the presence of proteinase K (PK)-resistant PrP (PrPSc). Three replicates containing only
uninfected brain homogenate were always run concurrently as negative controls.
Immunoblotting. SDS-PAGE/Western blot detection of soil-bound PrP and
PMCA samples was performed as described previously (14) without modification. Briefly, proteins were desorbed from soil (if soil bound) and denatured by
boiling samples in SDS-PAGE buffer (Laemmli buffer containing 2% SDS) at

100°C for 10 min. After electrophoresis using 12.5% acrylamide gels, transfer to
polyvinylidene difluoride (PVDF) membranes, and blocking in Blotto, blots were
probed with monoclonal antibody (MAb) 3F4 (Chemicon, Temecula, CA) (1:
10,000 dilution) and developed with Pierce SuperSignal West Femto maximumsensitivity substrate (Thermo Scientific, Rockford, IL). For proteinase K digestion, samples were incubated at 37°C under constant agitation for 30 min with 25
g PK (Roche Diagnostics) per ml of sample. PK digestion was terminated by
boiling in SDS-PAGE buffer.

RESULTS AND DISCUSSION
Enzymatic digestion of soil-bound PrPSc. The subtilisin enzyme treatment yielded complete or near-complete loss of
soil-bound HY PrPSc (Fig. 1), which agrees with previous results (14). A weak PrPSc signal did remain for SCL soil, bentonite, and SiO2 powder following subtilisin digestion and was
most easily detected following PK digestion (4 to 14% compared with untreated controls) (Fig. 1B and C). The unbound
PrPSc signal was decreased but remained strong following digestion (57%) (Fig. 1A and B, lanes 3). After the 7-day incubation, both treated and untreated humic acid (SiO2-HA) samples were very faint or undetectable (Fig. 1A and B, lanes 8 and
9), as were all sand samples except for the untreated, PKdigested replicates (Fig. 1B, lanes 12 and 13, and C). Overall,

FIG. 1. Subtilisin enzyme treatment of soil-bound HY TME PrP.
Representative Western blots (n ⫽ 3) of treated and untreated samples after 7 days of treatment with a 10% Prionzyme dose at 22°C are
shown. Imaged soil amounts are shown in Table 1. (A) No proteinase
K (PK) digestion prior to detection. (B) PK digestion prior to
detection. (C) Quantification of results shown in panel B. Error
bars show ⫾1 standard error of the mean. BH, brain homogenate.
Soil abbreviations: SCL, silty clay loam soil; SiO2HA, humic acidcoated silica beads; SiO2, silicon dioxide powder.
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FIG. 2. Quantitative serial PMCA of unbound HY TME prions.
Results for triplicate 10-fold serial dilutions of HY TME agent-infected brain homogenate using two different PMCA protocols are
shown. Error bars show ⫾1 standard error of the mean. y axes show the
oral (p.o.), extranasal (e.n.), and intracerebral (i.c.) infectious titers of the
brain homogenate dilutions (7). Values below 0 indicate less than 1 LD50.

Sc

these results indicate large decreases in soil-bound PrP following subtilisin enzyme digestion and suggest significant reductions in the infectivity of treated soil samples.
Development of quantitative serial PMCA protocol. To explore the relationship between PMCA efficiency and sample
titer, three replicates of a 10-fold serial dilution of a 10% HY
TME agent-infected brain homogenate were subjected to up to
seven rounds of serial PMCA using one of two protocols, as
described above. Figure 2 reports on the first PMCA round,
where a distinguishable positive PrPSc Western blot signal was
observed for each dilution. The infectious titer of an HY TME
agent-infected brain at terminal disease that we used in this study
contains 109.3 intracerebral (i.c.) 50% lethal doses (LD50),
103.7oral (per os) LD50, and 105.5 extranasal (e.n.) LD50 per g
of brain by endpoint titration (7). Using protocol 1, the highest
dose (a 10⫺1 homogenate dilution) was readily detected without PMCA, while the next three dilutions were detected after
one round. For higher dilutions, an approximately linear relationship existed between spiked titer and initial positive PMCA
round. Protocol 2, employing a shorter sonication time and
higher interround dilutions, yielded faster amplification, with a
10⫺11 homogenate dilution detectable after only three PMCA
rounds. PrPSc was not detected in the negative controls (n ⫽ 3)
for either protocol (data not shown).
These results show a strong, replicable correlation between
PMCA efficiency (i.e., the number of rounds required for a
positive signal) and the infectious titer of HY TME agentinfected brain homogenate samples. Although protocol 1 required more rounds of PMCA to amplify low levels of infectivity, the larger range of PMCA rounds allowed for better
quantification of differences in amplification efficiency. The
error of the standard curves shown in Fig. 2 could undoubtedly
be reduced by using additional replicates. Although it was
beyond the scope of this study to perform an in-depth evaluation of the differences in amplification over a range of PMCA
protocols, our results do demonstrate how protocols can be
modified to yield maximum amplification or maximum quantification resolution.
Chen et al. recently reported use of a quantitative sPMCA
protocol (4). However, their resolving power was ⫾2 to 4 logs
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FIG. 3. Inhibition of PMCA due to the presence of a subtilisin
enzyme solution. Representative Western blots (n ⫽ 3) of 1:100 HY
TME agent samples spiked with a serial dilution of the Prionzyme
solution and subjected to one round of PMCA are shown. Arrows
indicate the Prionzyme treatment dose (10%) and calculated postwash
concentration (10⫺4.9).

of PrPSc, analogous to that of our protocol 2. While their use
of dilutions of enriched PrPSc for the standard curve is potentially useful for quantifying PrPSc levels in fluids and tissues, it
may prove to be less helpful in evaluating sample infectivity
than using brain dilutions with known titers. Our results suggest that a standard curve of tissue dilutions with known titers
generated by sPMCA could be used to quantify sample infectivity, although additional validation work would clearly be
required before such an application. It has previously been
shown that PMCA efficiency varies with prion strain (1) and
species (15); thus, standard curves would need to be developed
for each strain and species used.
PMCA of subtilisin-treated soil samples. To evaluate any inhibitory effects of the subtilisin solution on the PMCA method, a
10-fold serial dilution of Prionzyme was spiked into identically
prepared samples of HY TME agent (1:100 ratio of HY-infected brain homogenate to PMCA substrate), which were
then subjected to one round of PMCA (protocol 1). The subtilisin solution completely inhibited HY PrPSc amplification
down to a 10⫺3 dilution (Fig. 3). It is likely that this inhibition
was due to subtilisin digestion of PrPc and/or other conversion
cofactors in the PMCA substrate. Given this inhibition, we
employed a washing step for soil samples (applied to both
treated and untreated samples) to lower the subtilisin concentration below inhibitory levels. Soils samples were diluted 1 to

FIG. 4. Serial PMCA of treated and untreated soil-bound HY
TME prions. Results for triplicate treated and untreated samples using
protocol 1 are shown. Error bars show ⫾1 standard error of the mean.
*, treated SiO2-HA samples were not positive through 8 rounds.
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20 in 1⫻ DPBS and then centrifuged (100 ⫻ g) to pellet soil
particles. The supernatant was removed and this process was
repeated twice more, diluting the calculated subtilisin concentration from 10⫺1 to 10⫺4.9. Unfortunately, this washing step
could not be performed on unbound samples, since this would
dilute not only the subtilisin but also the unbound HY TME
agent. Thus, the effectiveness of the enzyme treatment on
unbound HY TME agent could not be evaluated.
Treated and untreated soil-bound prions were subjected to
both PMCA protocol 1 and protocol 2. Soil amounts used for
PMCA seeding are shown in Table 1. Figure 4 shows the mean
positive round (three replicates) for each soil type. A significant increase between treated and untreated samples was observed for all soil types (P ⬍ 0.05 by t test assuming unequal
variance [GraphPad Prism, San Diego, CA]). The results using
protocol 2 were consistent with protocol 1 results, albeit with
smaller differences in mean positive round (data not shown).
Note that the presence of soil without PrPSc does not induce
PrPSc formation through three PMCA rounds (15).
The soil type influenced the effectiveness of enzymatic degradation of soil-bound HY TME agent (Table 1). The subtilisin was least effective at decreasing the PMCA efficiency of
HY bound to SiO2 and sand samples (2- or 3-round extensions). It was more effective for SCL soil and bentonite (5round extensions) and was especially effective against humic
acid (SiO2-HA)-bound prions, which failed to amplify in any
experiment following treatment. Overall, these results further
demonstrate that soil-bound prions are not necessarily protected from enzymatic digestion and that the subtilisin appears
to be broadly effective against prions bound to a range of soils.
We have previously shown that sand- and SiO2-bound prions
(untreated) have higher PMCA efficiencies than SCL soil-,
bentonite-, and SiO2-HA-bound prions (15). Moreover, we did
not observe consistent variance in enzyme effectiveness against
bound PrPSc (i.e., Western blot results) with respect to soil
type (Fig. 1) (14). Thus, the variance in enzyme effectiveness
observed in this study may be due to variance in the PMCA
efficiency of remaining (undigested) soil-bound prions and not
due to variance in the ability of the subtilisin to digest prions
bound to different soils.
Inhibition of soil-bound prion replication with an enzyme
solution. A key motivation for this work was determining the
efficacy of a topically applied enzyme treatment for reducing
prion infectivity on environmental surfaces such as soil,
thereby potentially reducing the risk of prion disease transmission from an environmental reservoir. Using the data presented in Fig. 2 and Fig. 4 (from protocol 1), it is possible to
correlate the mean positive PMCA round for treated and untreated soil samples with a corresponding PMCA efficiency of
known HY TME agent-infected brain homogenate titer (Table
2). The observed increases in PMCA rounds required for a
positive PrPSc detection following enzymatic treatment correspond to reductions in infectious HY TME titer of 104
(SiO2), 104.5 (sand), 105 (bentonite), 106.5 (SCL soil), and
⬎106.5 (SiO2-HA), suggesting large decreases in sample infectivity. It has previously been shown that the presence of soil can
inhibit the PMCA method (and that this inhibition is not soil
dependent) (15). Furthermore, taking into account this inhibition, prions bound to SCL soil, bentonite, and SiO2-HA exhibit
reduced PMCA efficiency compared to prions bound to SiO2

APPL. ENVIRON. MICROBIOL.
TABLE 2. Estimated reductions in equivalent HY TME agent titer
based on PMCA efficiency
Soil or mineral

SCL soil
Bentonite clay
SiO2-HA
SiO2 powder
Sand
a

Equivalent titer (HY TME agent
i.c. log LD50)
Untreateda

Treated

4
3.5
3.5
5
5

⫺2.5
⫺1.5
⬍⫺3
1
0.5

Untreated equivalent titers are based in part on reference 15.

and sand and to unbound controls. At least in the case of SCL
soil, this reduction in PMCA replication corresponds to a reduction in intracerebral infectious titer (15). These previous
results were considered when estimating the equivalent titers
of untreated samples (Table 2), since a range of titers are
readily amplified after one PMCA round.
It is important to note that this work was conducted using
HY TME hamster prions, with which we have extensive previous PMCA experience (1, 15, 17). HY TME prion interactions with soil may not necessarily recapitulate that of CWD or
other naturally occurring prions (11, 13); nevertheless, we previously observed equal or greater susceptibility to subtilisin
digestion for soil-bound CWD PrPSc compared with HY TME
PrPSc (14). Thus, it could be reasonably inferred that treated
soil-bound CWD prions would exhibit similar decreases in
PMCA replication efficiency.
The decisive test for prion infectivity remains animal bioassay, and thus, to demonstrate definitive decreases in infectivity
of soil-bound prions due to enzymatic treatment, bioassay will
need to be completed. Nevertheless, the subtilisin used (Prionzyme) has a high efficacy for reducing infectivity of unbound
prions. A previous study observed a 7-log decrease in 301V
mouse prions when using the Prionzyme at pH 12 and 60°C (6).
Moreover, our previous work using PMCA with soil has supported its use in correlating sample PMCA efficiency and infectivity (15). Thus, the significant decrease in replication efficiency observed for subtilisin-treated soil samples in the
present study is highly indicative of significant decreases in
infectious titer. We therefore propose that a mild enzymatic
treatment of environmental surfaces, whether using Prionzyme
or an alternative enzyme, could potentially reduce the risk of
CWD or scrapie transmission in the environment. We suggest
that locating environmental “hot spots” of prion infectivity is
now the most significant priority for applying a pilot-scale
enzyme treatment program to attempt to lower the risk of
environmental prion disease transmission.
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